Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Fat metabolism, inflammation reduction, and deeper aging biomarkers improve over 36 months
A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma:the RILOMET-2 trial [abstract]
: ( EGR-1),
Extraction techniques were reported to influence the quantity of active substances and the diversity of minor compounds, which resulted in differences in the pharmacokinetic parameters
Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome
.webp)
US$ 28.44
US$ 25.88
US$ 27.17
US$ 25.43
.png)
US$ 25.18
US$ 22.97
US$ 21.02
US$ 24.92
US$ 21.28
US$ 23.05
US$ 20.88
US$ 20.20
US$ 24.95
